×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ADAG – adagene inc. - ads, each representing 1.25 ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ADAG
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/6
08:02 am
adag
Adagene (ADAG) had its price target raised by Guggenheim from $9.00 to $10.00. They now have a "buy" rating on the stock.
High
Report
Adagene (ADAG) had its price target raised by Guggenheim from $9.00 to $10.00. They now have a "buy" rating on the stock.
4/2
08:09 pm
adag
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs [Yahoo! Finance]
Medium
Report
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs [Yahoo! Finance]
4/2
08:42 am
adag
Adagene announces pricing of $70M public offering of ADS [Seeking Alpha]
Medium
Report
Adagene announces pricing of $70M public offering of ADS [Seeking Alpha]
4/2
07:10 am
adag
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
Medium
Report
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
4/2
07:01 am
adag
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
High
Report
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
4/2
07:00 am
adag
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
High
Report
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
4/2
02:25 am
adag
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
4/1
05:00 pm
adag
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
High
Report
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
4/2
07:12 am
adag
Form 6-K Adagene Inc. For: Apr 02
Low
Report
Form 6-K Adagene Inc. For: Apr 02
4/2
07:00 am
adag
Form 6-K Adagene Inc. For: Apr 02
High
Report
Form 6-K Adagene Inc. For: Apr 02
4/1
05:16 pm
adag
Form 6-K Adagene Inc. For: Apr 01
High
Report
Form 6-K Adagene Inc. For: Apr 01
4/1
05:16 pm
adag
Form 20-F Adagene Inc. For: Dec 31
High
Report
Form 20-F Adagene Inc. For: Dec 31
3/18
09:23 am
adag
Form SCHEDULE 13G Adagene Inc. Filed by: Chernett Jorey
Low
Report
Form SCHEDULE 13G Adagene Inc. Filed by: Chernett Jorey
3/18
09:05 am
adag
Form 3 Adagene Inc. For: Mar 18 Filed by: Chane-Du Mickael Yannick
Low
Report
Form 3 Adagene Inc. For: Mar 18 Filed by: Chane-Du Mickael Yannick
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: